Interestingly, loss of CDKN2 proteins in meningiomas has been established as an important consideration for tumor classification and, in some cases, a determinant of tumor progression (Goutagny et al., 2010; Suppiah et al., 2019). This evidence concerns the gene CDKN2A and meningioma.